(See also Overview of Histiocytic Syndromes Overview of Histiocytic Disorders The histiocytic disorders are clinically heterogeneous disorders that result from an abnormal proliferation of histiocytes that are either Monocyte-macrophages (antigen-processing cells) Dendritic... read more .)
Hemophagocytic lymphohistiocytosis (HLH) is uncommon. It affects mostly infants < 18 months. It involves a defect in targeted killing and the inhibitory controls of natural killer and cytotoxic T cells, resulting in excessive cytokine production and accumulation of activated T cells and macrophages in various organs. Cells in the bone marrow and/or spleen may attack red blood cells, white blood cells, and/or platelets.
HLH can be
HLH is diagnosed when patients fulfill at least 5 of the criteria described below or have a mutation in a known HLH-associated gene.
Acquired HLH can be associated with infections (eg, Epstein-Barr virus Infectious Mononucleosis Infectious mononucleosis is caused by Epstein-Barr virus (EBV, human herpesvirus type 4) and is characterized by fatigue, fever, pharyngitis, and lymphadenopathy. Fatigue may persist weeks or... read more , cytomegalovirus Cytomegalovirus (CMV) Infection Cytomegalovirus (CMV, human herpesvirus type 5) can cause infections that have a wide range of severity. A syndrome of infectious mononucleosis that lacks severe pharyngitis is common. Severe... read more , or others), cancer (eg, leukemias Overview of Leukemia Leukemia is a malignant condition involving the excess production of immature or abnormal leukocytes, which eventually suppresses the production of normal blood cells and results in symptoms... read more , lymphomas Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. The major types are Hodgkin lymphoma and non-Hodgkin lymphoma (see table Comparison of... read more ), immune disorders (eg, systemic lupus erythematosus Systemic Lupus Erythematosus (SLE) Systemic lupus erythematosus is a chronic, multisystem, inflammatory disorder of autoimmune etiology, occurring predominantly in young women. Common manifestations may include arthralgias and... read more , rheumatoid arthritis Rheumatoid Arthritis (RA) Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily involves the joints. RA causes damage mediated by cytokines, chemokines, and metalloproteases. Characteristically... read more , polyarteritis nodosa Polyarteritis Nodosa (PAN) Polyarteritis nodosa is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries and occasionally affects small muscular arteries, resulting in secondary tissue... read more , sarcoidosis Sarcoidosis Sarcoidosis is an inflammatory disorder resulting in noncaseating granulomas in one or more organs and tissues; etiology is unknown. The lungs and lymphatic system are most often affected, but... read more , progressive systemic sclerosis Systemic Sclerosis Systemic sclerosis is a rare chronic disease of unknown cause characterized by diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs (especially the esophagus... read more , Sjögren syndrome Sjögren Syndrome Sjögren syndrome is a relatively common chronic, autoimmune, systemic, inflammatory disorder of unknown cause. It is characterized by dryness of the mouth, eyes, and other mucous membranes due... read more , Kawasaki disease Kawasaki Disease Kawasaki disease is a vasculitis, sometimes involving the coronary arteries, that tends to occur in infants and children between the ages of 1 year and 8 years. It is characterized by prolonged... read more ) and can occur in kidney or liver transplant recipients.
In both familial and acquired forms, genetic abnormalities, clinical manifestations, and outcomes tend to be similar.
Hemophagocytic lymphohistiocytosis can be diagnosed if there is a mutation in a known causative gene or if at least 5 of 8 diagnostic criteria are met:
Fever (peak temperature of > 38.5° C for > 7 days)
Splenomegaly (spleen palpable > 3 cm below costal margin)
Cytopenia involving > 2 cell lines (hemoglobin < 9 g/dL [90 g/L], absolute neutrophil count < 100/mcL [0.10 × 109/L], platelets < 100,000/mcL [100 × 109/L])
Hypertriglyceridemia (fasting triglycerides > 177 mg/dL [2.0 mmol/L] or > 3 standard deviations [SD] more than normal value for age) or hypofibrinogenemia (fibrinogen < 150 mg/dL [1.5 g/L] or > 3 SD less than normal value for age)
Hemophagocytosis (in biopsy samples of bone marrow, spleen, or lymph nodes)
Low or absent natural killer cell activity
Serum ferritin > 500 ng/mL (> 1123.5 pmol/Lng/mL)
Elevated soluble interleukin-2 (CD25) levels (>2400 U/mL or very high for age)
Genetic mutations associated with HLH include
Because some of these tests may not be widely available and HLH is uncommon, patients are usually referred to specialized centers for evaluation.
Treatment for hemophagocytic lymphohistiocytosis should be started if the disorder is suspected, even if not all diagnostic criteria are fulfilled. Patients are usually treated by a pediatric hematologist and in a referral center experienced in treating patients with HLH. Treatment depends on the presence of factors such as a family history of HLH, coexisting infections, and demonstrated immune system defects. Treatment for HLH may include cytokine inhibitors, immune therapy, chemotherapy, some combination of these, and possibly stem cell transplantation Hematopoietic Stem Cell Transplantation Hematopoietic stem cell (HSC) transplantation is a rapidly evolving technique that offers a potential cure for hematologic cancers (leukemias, lymphomas, myeloma) and other hematologic disorders... read more .
In 2018, emapalumab, an interferon gamma–blocking monoclonal antibody, became available for patients with refractory, recurrent, or progressive HLH or with an intolerance to conventional therapy.
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon rare disorder and usually affects infants < 18 months.
HLH can be familial (inherited) or acquired.
Diagnose HLH if the patient has at least 5 of 8 published diagnostic criteria or if the patient has a known mutation associated with HLH.
Treat with chemotherapy, cytokine inhibitors, immune suppression, and sometimes hematopoietic stem cell transplantation.
Drugs Mentioned In This Article
|Drug Name||Select Trade|